Pharmaceuticals

Global Tremfya Market Forecast 2026–2035: Long-Term Growth Insights

March 6, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the tremfya market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Tremfya Market expected to grow between 2026 and 2030?

The historical growth can be attributed to a rising incidence of psoriasis and psoriatic arthritis. This was further supported by the demonstrated efficacy of biologic treatments, the growth of specialized dermatology services, enhanced patient commitment to biologic regimens, and more extensive reimbursement policies for biologic medications.

The expansion observed during the forecast period is fueled by a heightened need for enduring inflammatory condition care, the extension of biologics into digestive health applications, a developing inclination towards less frequent drug administration, escalating capital directed towards monoclonal antibody-based treatments, and an intensifying emphasis on customized immunological therapeutic approaches.

Significant developments anticipated in the forecast period involve a wider acceptance of IL-23 inhibitor treatments, an escalating call for biologic therapies administered at longer intervals, the broadening of conditions recognized as autoimmune diseases, more frequent utilization of injectable biologics under the skin, and a sharpened concentration on precisely targeting immune system modulation.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp

Which Drivers Are Influencing Market Acceleration In The Tremfya Market?

The expanding occurrence of autoimmune conditions is anticipated to fuel the future expansion of the tremfya market. These illnesses involve the body’s immune system erroneously assaulting its own cells, tissues, or organs, treating them as external threats. The growing frequency of autoimmune diseases stems from factors such as genetic susceptibility, environmental instigators, shifts in lifestyle, enhanced public awareness, and advancements in diagnostic methods. Tremfya, a monoclonal antibody designed to target interleukin-23 (IL-23), assists in treating autoimmune diseases by moderating the immune system’s excessive activity, thereby decreasing inflammation and easing symptoms in conditions like psoriasis and psoriatic arthritis. As an illustration, in February 2024, data from Arthritis Australia, an Australia-based non-profit organization, indicated that in 2025, roughly 212,136 males and 362,137 females are forecast to suffer from rheumatoid arthritis (RA), with these figures predicted to climb by 2040 to around 280,040 males and 479,828 females. Consequently, the increasing prevalence of autoimmune diseases is accelerating the expansion of the tremfya market.

What Segments Are Identified Within The Structure Of The Tremfya Market?

The tremfya market covered in this report is segmented –

1) By Indication: Moderate-To-Severe Plaque Psoriasis, Active PsA

2) By Formulation: Subcutaneous Injection, Intravenous Infusion

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

4) By End User: Adult Patients, Geriatric Patients

What Upcoming Trends Are Likely To Define The Future Path Of The Tremfya Market?

Leading entities within the TREMFYA sector are securing regulatory authorizations to broaden its therapeutic applications, encompassing conditions like moderate-to-severe Crohn’s disease, thereby expanding its user demographic and commercial prospects. Such regulatory clearances denote formal permissions issued by bodies including the Food and Drug Administration (FDA) or European Medicines Agency (EMA), permitting a medication’s sale for particular purposes once its safety, effectiveness, and quality have been established. As an illustration, in September 2024, Johnson & Johnson, an American pharmaceutical firm, obtained FDA consent for TREMFYA (guselkumab) specifically for managing moderately to severely active ulcerative colitis in adults, establishing it as the inaugural dual-acting interleukin-23 inhibitor sanctioned for this ailment. This determination stems from favorable outcomes observed in the Phase 2b/3 QUASAR study, which revealed that roughly 50% of participants achieved clinical remission following 44 weeks of therapy. TREMFYA functions by targeting interleukin-23, thus aiding in the normalization of the colon’s inflammatory response.

Which Key Market Players Are Investing In Expansion And Innovation Within The Tremfya Market?

Major companies operating in the tremfya market are Johnson & Johnson

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Tremfya Market?

North America was the largest region in the tremfy market in 2025. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Tremfya Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20343&type=smp

Browse Through More Reports Similar to the Global Tremfya Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Financial Analytics Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795